发明名称 Histone deacetylase inhibitors
摘要 This invention relates to generally inhibiting histone deacetylase (HDAC) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
申请公布号 US9540395(B2) 申请公布日期 2017.01.10
申请号 US201213823708 申请日期 2012.02.28
申请人 BIOMARIN PHARMACEUTICAL INC. 发明人 Jacques Vincent;Rusche James R.;Peet Norton P.;Singh Jasbir
分类号 C07D277/30;C07D231/00;C07D263/34;C07D261/06;C07D233/00;C07D209/02;C07D405/00;C07D409/00;C07D411/02;C07D491/02;C07D498/02;C07D211/06;C07D211/68;C07D211/80;C07D213/02;C07D513/04;C07D211/70;C07D231/12;C07D263/32;C07D401/06;C07D403/06;C07D471/04;C07D211/34;C07D233/64;C07D261/08;C07D401/00;C07D421/00;A61K31/00;A61K31/425;A61K31/415;A61K31/42;A61K31/44;A61K31/445 主分类号 C07D277/30
代理机构 Marshall, Gerstein & Borun LLP 代理人 Marshall, Gerstein & Borun LLP
主权项 1. A compound of the formula (I):wherein Ar/Het is selected from the group consisting of pyrazolyl, thiazolyl, oxazolyl, imidazolyl, thienyl, furanyl, isoxazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, and 1,2,4-triazolyl; Y is bond, CRc═CRd, O, NRe, or S(O)m; a is 1-3; b is 0-3; m is 0-2; each occurrence of Ra and Rb is independently selected from H, F, OH, C1-C6 alkyl, C3-C6 cycloalkyl, NH2, OCO—(C1-C6 alkyl), OCO—(C3-C6 cycloalkyl), C1-C6 alkoxy, C1-C6 fluoroalkoxy, and cyano; each of Rc and Rd is, independently, selected from H, F, OH, C1-C6 alkyl, C3-C5 cycloalkyl, NH2, OCO—(C1-C6 alkyl), OCO—(C3-C5 cycloalkyl), C1-C6 alkoxy, C1-C6 fluoroalkoxy, and cyano; each occurrence of Re is independently selected from H, C1-C6 alkyl, —C(═O)H, —C(═O)Rh, C(═O)O(C1-C6 alkyl), C(═O)N(Ri)2, SO2—Rh, wherein Rh is selected from C1-C6 alkyl, CH2-(heteroaryl having 5-10 ring atoms), CH2—(C6-C10 aryl), and C6-C10 aryl; and each occurrence of Ri is independently selected from H, C1-C6 alkyl, CH2-(heteroaryl having 5-10 ring atoms), CH2—(C6-C10 aryl), and C6-C10 aryl and the aryl or heteroaryl portion in Rh and Ri can be optionally substituted with one or more independently selected substituents selected from the group consisting of F, C1-C6 alkyl, fluoro C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 fluoroalkoxy, and cyano; each of R4 and R5 is, independently, selected from H, C1-C6 alkyl and F; R1 is: (i) hydrogen; or (ii) C6-C10 aryl, which is optionally substituted with from 1-3 Ro; or (iii) monocyclic or bicyclic heteroaryl having from 5-10 ring atoms, which is optionally substituted with from 1-3 Ro; wherein from 1-4 of the ring atoms is/are a heteroatom independently selected from O, N, N—H, N—Ro, and S; or (iv) heterocyclyl having from 4-10 ring atoms, which is optionally substituted with from 1-3 Ro; wherein from 1-4 of the ring atoms is/are a heteroatom independently selected from O, N, N—H, N—Ro, and S; and each occurrence of Ro is independently selected from the group consisting of: halogen; C1-C6 alkyl; fluoro(C1-C6alkyl); hydroxyl; hydroxy(C1-C4alkyl); C1-C6 alkoxy; fluoro(C1-C6alkoxy); (C1-C6 alkyl)C(O)—; (C1-C6 alkyl)NH—; (C1-C6 alkyl)2N—; formyl; formyl(C1-C4alkyl); cyano; cyano(C1-C4alkyl); benzyl; benzyloxy; SO2—(C1-C6alkyl); SO—(C1-C6alkyl); and nitro; R2 is selected from H, F, Cl, CF3, CF2CF3, CH2CF3, OCF3, OCHF2, phenyl; phenyl substituted with from 1-3 substituents independently selected from F, OH, C1-C6 alkyl, fluoro(C1-C6 alkyl) C3-C6 cycloalkyl, NH2, C1-C6 alkoxy, C1-C6 fluoroalkoxy, and cyano; thienyl; thiazolyl; and pyrazol-1-yl; and R3 is H, F, or Cl;or a pharmaceutically acceptable salt thereof.
地址 Novato CA US